All News

Elamipretide Improves Fertility Measures in Aged Mice

By Sandy Martin•November 16, 2026

In aged female mice, seven days of elamipretide improved oocyte quality, fertilization, embryo development and litter size—a preclinical signal that mitochondrial function may be a tractable target in reproductive aging.

A short course of a mitochondria-targeting peptide improved several measures of reproductive function in aged female mice. In a peer-reviewed preclinical study, seven days of elamipretide treatment improved ovarian follicle measures, oocyte fertilization, early embryonic development and litter size. Some reproductive benefits remained detectable for approximately one month after treatment.

The result, also described in a LifeSpan.io report on elamipretide and ovarian aging, is best understood as a functional rescue in an animal model—not evidence that ovarian aging has been delayed in women. Even so, the breadth of the mouse findings makes the peptide a notable candidate for further reproductive-aging research.

A seven-day treatment changed several reproductive measures

The investigators studied female mice aged 8 or 10 months and tested different doses and treatment schedules. A dose of 5 milligrams per kilogram for seven days was reported as the most effective regimen.

The study assessed more than the appearance of ovarian tissue. It examined follicle measures, oocyte maturation and fertilization, embryo development and reproductive performance. Elamipretide-treated aged mice produced larger litters, and the improvement in reproductive performance persisted for about a month after dosing ended.

That combination is important because reproductive aging is not captured by one laboratory marker. An ovary may still contain follicles while producing oocytes that are less able to mature, segregate chromosomes correctly, support fertilization or sustain early embryonic development. By examining outcomes across this sequence, the study connected molecular and cellular changes with an organism-level result.

The design nevertheless addresses recovery rather than prevention. The researchers treated mice that were already reproductively aged; they did not begin treatment in young animals and follow them across life to determine whether the onset of reproductive decline was postponed. “Improved age-associated reproductive measures” is therefore more precise than claiming that the intervention stopped ovarian aging.

Why mitochondria are central to the hypothesis

Elamipretide, also known as SS-31, is a peptide made from four amino acids. It is designed to accumulate at the inner mitochondrial membrane and interact with cardiolipin, a lipid important to membrane structure and energy production. Independent mechanistic literature describes the compound as potentially stabilizing this membrane, supporting respiratory-chain function and limiting excessive production of reactive oxygen species, although these proposed actions do not themselves prove a fertility benefit in people.

That mechanism is relevant because oocyte maturation is unusually dependent on coordinated energy production. Nuclear maturation requires the meiotic spindle to organize and separate chromosomes. Cytoplasmic maturation involves the redistribution of mitochondria and the accumulation of molecules needed for fertilization and early development. Disruption in either domain can reduce developmental competence.

The study’s functional findings are consistent with a mitochondrial mechanism, but they do not reduce reproductive aging to a single source of damage. Ovarian aging also encompasses changes in follicles, supporting cells and local signaling. Elamipretide could influence several of these processes through altered energy metabolism and redox balance.

Metabolic profiling offers clues to the response

To look beyond reproductive outcomes, the researchers compared metabolites in young ovaries, aged ovaries and aged ovaries exposed to elamipretide. They identified 250 metabolites whose abundance differed between the young and aged groups. Treatment partially shifted this age-associated metabolic profile rather than restoring every measured feature to a young state.

Pyruvate, a central input into mitochondrial energy metabolism, was among the molecules affected. The investigators observed lower pyruvate levels with ovarian aging and linked the treatment response to pathways involving pyruvate and vitamin B6 metabolism.

Vitamin B6 supplementation also improved oocyte-quality measures in aged mice in an accompanying experiment. This makes B6 metabolism a mechanistic clue, but it does not show that taking vitamin B6 would reproduce elamipretide’s effects or improve fertility in women. Nutrient supplementation and a mitochondria-targeting peptide are different interventions, and the mouse experiment was designed to investigate a pathway rather than establish a clinical regimen.

Gene-expression analysis additionally implicated vascular endothelial growth factor signaling. Experiments involving VEGF-A supported a possible role for this pathway in the quality of aged oocytes. Together, the metabolic and gene-expression findings suggest that the reproductive effects may arise from linked changes in mitochondrial metabolism and cellular signaling, rather than from one isolated molecular switch.

Human oocytes add relevance, but not a clinical result

The same study exposed human oocytes to elamipretide in vitro and reported improvements in maturation, fertilization and cleavage-related measures. These observations are more directly relevant to human cell biology than mouse data alone, but they remain laboratory findings. No women received the peptide, and the experiment could not assess systemic dosing, pregnancy, live birth or longer-term reproductive safety.

A separate preclinical study of SS-31 provides convergent evidence at the cellular level. When aged mouse oocytes were supplemented with the peptide in vitro, researchers reported better maturation, spindle and chromosome organization, fertilization and mitochondrial distribution, alongside lower measures of aneuploidy, oxidative stress and DNA damage.

That study strengthens the case that mitochondrial dysfunction is connected to specific deficits in aged oocytes. It does not, however, establish that systemic treatment can safely improve human reproductive outcomes. An oocyte in culture is removed from the hormonal, vascular and cellular environment of the ovary, while a fertility treatment must work within that entire system.

A development signal for reproductive biotechnology

The practical value of this research lies in the evidence chain it begins to assemble. Elamipretide affected mitochondrial and metabolic measures, improved several properties of aged oocytes, supported embryo development and increased litter size in mice. The inclusion of functional reproductive outcomes makes the study more informative than work based only on molecular markers.

For drug development, it also supplies a candidate dosing schedule in mice, potential metabolic biomarkers and cellular endpoints that could be tested in further studies. Research would still need to establish an appropriate human dose, characterize reproductive and offspring safety, and determine whether laboratory improvements translate into pregnancy or live-birth benefits.

For patients and practitioners, the study does not establish elamipretide as a fertility treatment or justify using vitamin B6 as a substitute. Its more immediate contribution is scientific: it suggests that at least some age-associated loss of oocyte competence may be modifiable through mitochondrial pathways, rather than being entirely irreversible. Whether that possibility can become a safe and effective therapy for women is now a clinical question, not one the mouse results can answer.